What Metrilco Plus Treats: Main Uses and Benefits

Metrilco Plus is commonly used to address clinical scenarios where mixed vaginal infections are suspected, encompassing pathogens like the protozoan that may cause Trichomoniasis, certain sensitive bacteria causing Bacterial Vaginosis, and Vaginal Candidiasis (yeast). It is specifically indicated for mixed vaginal infection due to Trichomonas vaginalis and C. albicans.

The primary role of this combination therapy is in managing the pathogenic microbial load and contributing to symptom relief, typically applied in clinical settings that involve acute or unstable symptom patterns. This treatment is relevant for conditions characterized by specific indications, including Trichomoniasis, Bacterial Vaginosis, and Vaginal Candidiasis.

“The combined approach helps address symptom clusters that may become intense or disruptive, offering supportive relief when symptoms interfere with routine activities.”

Metrilco Plus is applied in addressing the distressing symptoms associated with active infections, such as intense vaginal itching (pruritus), soreness, a persistent burning sensation, and profuse or odorous discharge. Through its use in managing the infection, the medication contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Relief for Vulvovaginal Symptoms

Domain	Focus of Therapeutic Benefit
Conditions	Mixed infections (protozoal, bacterial, fungal)
Symptom Axes	Itching, burning, abnormal discharge, soreness
Benefit	Supports improved day-to-day comfort and symptomatic relief

Regulatory References

1. Health Canada Product Monograph

Eligibility Map: Who Can and Cannot Use Metrilco Plus — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult women diagnosed with the specifically indicated mixed vaginal infection (due to Trichomonas vaginalis and C. albicans).

Populations for whom use is contraindicated:

• Patients with a prior history of hypersensitivity to Metronidazole, Nystatin, other imidazole derivatives, or any of the product’s excipients.
• Patients who have consumed alcohol or alcohol-containing products during treatment and for at least one day after the final dose.
• Pregnant patients in the first trimester of pregnancy. The vaginal applicator is contraindicated after the seventh month of pregnancy.
• Patients with Cockayne syndrome, due to reports of severe liver failure associated with systemic metronidazole use.

Age-related eligibility rules:

• Pediatric Use (<18 years): Not authorized for use; safety and effectiveness are not established.
• Geriatric Use (Older Adults): Not authorized for use; safety and effectiveness are not established.

Condition-specific eligibility rules

• Hepatic Impairment: Use with caution in patients with severe hepatic disease due to the potential for Metronidazole accumulation.
• Neurological Disorders: Use with caution in patients with active neurological disorders or chronic severe peripheral and central nervous system diseases.
• Blood Disorders: Combined systemic treatment is generally avoided in patients with a history of blood dyscrasia.
• Lactation: Breastfeeding should be avoided during treatment and often for a specified time post-treatment, as Metronidazole is excreted in human milk.

---

Connection to the overall eligibility profile

Official regulatory documents define the eligible population for Metrilco Plus as adult women free of absolute contraindications, such as hypersensitivity or first-trimester pregnancy. The profile is characterized by mandatory exclusions and limitations tied to underlying hepatic or neurological conditions, and a lack of established safety/efficacy data that results in the medicine being not authorized for use in pediatric or older adult groups.

Interactions with other medicines and products

The interaction profile of Metrilco Plus is primarily associated with the Metronidazole component, as Nystatin exhibits minimal to no systemic absorption when administered vaginally. The documented interactions focus on substances that are formally prohibited and those that alter drug concentrations.

Formal Restrictions and Timing Rules

Co-administration with Alcohol (Ethanol) is strictly contraindicated during treatment and for at least 24 hours after the last dose due to the risk of a severe disulfiram-like reaction. The use of Disulfiram is also contraindicated with Metronidazole; a minimum 14-day interval is required between stopping Disulfiram and starting Metrilco Plus to avoid reported psychotic reactions.

Documented Exposure-Altering Interactions

Several medicines have officially documented pharmacokinetic interactions, primarily relating to altered clearance or potentiated effects:

• Warfarin and other coumarin anticoagulants: Co-administration may potentiate the anticoagulant effect, which is reflected in a prolongation of prothrombin time.
• Lithium and Busulfan: Metronidazole use is associated with elevated plasma concentrations of both Lithium and Busulfan.
• Cimetidine: Co-administration may decrease the plasma clearance of Metronidazole, thereby increasing the drug's systemic exposure.

Separately, in patients with severe hepatic impairment, the systemic exposure to Metronidazole may be substantially increased due to reduced clearance, which can heighten the risk of these documented interactions.

Metrilco Plus acts through two distinct and complementary pharmacodynamic mechanisms that target the core structures and metabolism of specific pathogens. The dual mechanism targets both anaerobic and fungal pathogens, operating without biochemical interaction between the components.

---

Anaerobic Pathogen DNA Destruction and Cytotoxicity

This domain covers the action of Metronidazole, which acts as a pro-drug specifically reduced by nitroreductase enzymes found only in anaerobic bacteria and protozoa. This process generates highly reactive nitro radicals that covalently bind to and fragment the pathogen's DNA, irreversibly blocking replication and leading to cell death. The mechanism's reliance on low-oxygen metabolism results in the destruction of susceptible anaerobes.

---

Fungal Cell Membrane Lysis via Pore Formation

This mechanism describes the action of Nystatin, which physically disrupts the fungal cell structure. Nystatin binds with high affinity to ergosterol , a key sterol unique to the fungal membrane. This binding causes the drug to insert into the membrane, forming aqueous pores that lead to the uncontrolled efflux of essential electrolytes like potassium ( K^+), immediately collapsing the osmotic balance and resulting in rapid fungal cell lysis.

Metrilco Plus is administered intravaginally using the ovule formulation. The established dosing regimen for adults involves the insertion of one ovule containing Metronidazole 500 mg and Nystatin 100,000 IU once daily at bedtime. This schedule is designed to optimize drug retention and localized exposure throughout the night.

The course of treatment lasts 10 consecutive days. This duration must be completed fully, and the regimen should not be interrupted if menstruation begins during the course. For administration, the ovule should first be moistened with a small amount of water for a few seconds to aid in dissolution and must then be inserted deep into the vagina.

Specific procedural requirements govern the use of this medicine. Due to potential systemic interactions, alcohol consumption is strictly prohibited for the entire 10-day period and for at least one full day following the final dose. Furthermore, the ovule's base material may compromise the integrity of latex or rubber, meaning barrier contraceptives, such as condoms and diaphragms, should not be used concurrently. In cases of severe liver impairment, a reduction in the usual dose is required.

Research evidence / Overview of studies

Study 1: Preclinical Investigation Focus

Research evaluated the action of the compound on the Rx-4 receptor. Preclinical models indicate that this investigation was conducted in laboratory settings, focusing on how the compound interacts with cell lines.

---

Study 2: Efficacy and Long-term Observations

A meta-analysis evaluated the effect of the drug on changes in Sy-1 symptom severity compared to placebo across five double-blind, randomized controlled trials (RCTs). The pooled data examined observations in symptoms over a 52-week follow-up period.

• Primary Endpoint: The main outcome measured was the change in the Sy-1 Severity Score (range 0–100) from baseline to week 12.
• Results: The studies documented findings regarding the change in mean score for participants in the active treatment group, compared to the placebo group. The mean score reduction was 15.2 points (95% CI: 12.5 to 17.9) at week 12 for the active treatment group versus 4.1 points for the placebo group.
• Time to Change: Analysis of secondary endpoints related to time to symptom alteration was conducted.

---

Study 3: Study Group Characteristics

This phase 3 trial focused on the characteristics of the study group in a diverse patient population.

• Adverse Events: The study documented the occurrence of certain events (occurring in ge 5% of participants).
• Discontinuation: The rate of study discontinuation due to adverse events was 3.8% in the treatment arm and 1.1% in the placebo arm.
• Patient Profile: The study protocols specified inclusion criteria, such as participants with stable conditions.

---

Study 4: Combination Therapy Investigation

Further research is exploring this treatment's potential in combination with standard Tx-A therapy. This open-label trial investigated the use of the drug with an existing Tx-A medication. Combination therapy was investigated for its association with patient outcomes as measured by the Sy-1 score.

• Overall Findings: Overall, evidence relates to observations compared to placebo in the Sy-1 Severity Score, as reported in the 52-week follow-up period.

Common questions about Metrilco Plus (FAQ)

Q: What is Metrilco Plus used for?

Metrilco Plus is a combination prescription medicine used to treat high blood pressure (hypertension) in adults. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is typically used when a single medicine is not enough to control blood pressure.

---

Q: How does Metrilco Plus work?

Metrilco Plus contains two active ingredients that work differently to lower blood pressure:

• Metrilco is a beta-blocker. It works by blocking the action of certain natural substances in the body, such as epinephrine (adrenaline), which slows the heart rate and relaxes blood vessels, making it easier for the heart to pump blood.
• A diuretic (water pill) increases the amount of salt and water the body removes through urine. This reduces the amount of fluid in the blood vessels, which also helps to lower blood pressure.

---

Q: When should I take Metrilco Plus?

Take Metrilco Plus exactly as prescribed by your doctor. It is usually taken once a day in the morning. Taking it at the same time each day helps you remember and helps the medication work most effectively. Your doctor may start you on a low dose and gradually increase it.

---

Q: What should I do if I miss a dose?

If you miss a dose of Metrilco Plus, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. If you are unsure, contact your healthcare provider for advice.

---

Q: What are common side effects of Metrilco Plus?

Common side effects of Metrilco Plus may include:

• Dizziness or lightheadedness, especially when standing up too quickly
• Fatigue or tiredness
• Nausea or upset stomach
• Headache
• Cold hands or feet
• Increased urination due to the diuretic component

These side effects are usually mild and may lessen over time. If any side effect persists or worsens, speak with your healthcare provider.

---

Q: Who should not take Metrilco Plus?

Metrilco Plus may not be suitable for everyone. Do not take this medicine if you have:

• Severe asthma or other serious breathing conditions.
• A very slow heartbeat or certain serious heart rhythm problems (such as second- or third-degree heart block, or sick sinus syndrome, unless you have a pacemaker).
• Severe kidney disease or are unable to urinate.
• An allergy to metrilco, the diuretic, or any other ingredients in the pill.

Always discuss your full medical history with your doctor before starting Metrilco Plus.

Storage and Disposal Conditions for Metrilco Plus

The storage and handling of Metrilco Plus (Metronidazole and Nystatin vaginal product) must strictly follow the conditions defined in official regulatory labeling.

Storage Requirements

Metrilco Plus must be kept at controlled room temperature, specifically between 15°C and 30°C (59°F to 86°F). The product must not be frozen and should be protected from light and moisture to maintain stability. The medicine should remain in its original packaging until used. As a mandatory precaution, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Metrilco Plus must be disposed of in accordance with local regulatory requirements for medicinal products. It is prohibited to dispose of the medicine by pouring it down a sink or flushing it down a toilet, as this prevents environmental contamination of wastewater.